ArticleJournal of molecular modeling2026
Molecular modeling and quantum chemical calculation study of derived peptides from a Bowman-Birk inhibitor in complexes with trypsin.
Article in Journal of molecular modeling, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
contextBowman-Birk inhibitors (BBIs) are cysteine-rich proteins that inhibit trypsin and chymotrypsin proteases. Derived from soybeans, these natural BBIs have been identified as potential anticarcinogenic agents. Recent studies of the black-eyed pea trypsin/chymotrypsin inhibitor (BTCI) demonstrated that peptides derived from the BBI family may retain their structure and inhibitory activity. Therefore, this study aimed to investigate the effects of solvent on BTCI-derived peptides and their inhibitory activity against trypsin. The results show that cyclic peptides exhibit reduced conformational flexibility, enhanced reactivity (narrower HOMO-LUMO gap), and LUMO localized at the disulfide bonds, in contrast to the linear peptide Ptry6. Non-covalent interactions were evaluated using the Independent Gradient Model based on Hirshfeld partitioning (IGMH). Molecular electrostatic potential maps and the IGMH confirmed that the cyclic architecture concentrates electropositive donor regions at key residues (Thr2, Lys3, Ser4, and Ile5), whereas Ptry6 displays only weak van der Waals contacts. Docking studies against trypsin showed strong hydrogen-bond and electrostatic interactions between cyclic peptides and residues involved in the catalytic mechanism. Predicted inhibition constants obtained from docking studies closely match experimental data. These findings suggest that electronic redistribution upon solvation governs peptide-trypsin affinity, highlighting Ptry9L as the most promising BTCI-derived inhibitor for further biotechnological development.
methodsBTCI peptides were studied using quantum-chemical calculations and molecular docking. Three peptides-a cyclic nonapeptide in both L- and D-configurations (Ptry9L, Ptry9D) and a linear hexapeptide (Ptry6)-were optimized in vacuo and in implicit aqueous solvent using density functional theory at B3LYP-D3/Def2-SVP and B3LYP-D3/6-311+G(d,p) levels with D3 dispersion correction. Frontier molecular orbital analyses (HOMO-LUMO gaps and orbital localization) and IGMH revealed that the disulfide bond stabilizes cyclic peptides.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.